FibroScan / VCTE Longevity-Medicine Target Ranges

What FibroScan (VCTE) Actually Measures

Vibration-controlled transient elastography (VCTE), commercially sold as FibroScan by Echosens, sends a low-frequency mechanical wave through the liver and records how fast it travels. Stiffer tissue, meaning more collagen and fibrotic remodeling, propagates the wave faster. The device reports liver stiffness measurement (LSM) in kilopascals (kPa) and, via the simultaneous controlled attenuation parameter (CAP), estimates hepatic steatosis in decibels per meter (dB/m) [1].

Why kPa and Not Biopsy

Liver biopsy remains the histological reference standard, but it samples roughly 1/50,000 of total liver volume and carries a 0.5% serious complication rate [2]. VCTE samples a cylinder approximately 1 cm wide by 4 cm long, roughly 100 times the biopsy volume, making it a better representation of diffuse fibrosis distribution [1]. The 2023 EASL Clinical Practice Guideline on non-invasive tests rates VCTE as the preferred first-line non-invasive test for fibrosis assessment in MASLD (metabolic dysfunction-associated steatotic liver disease) [3].

The Controlled Attenuation Parameter

CAP is not a bonus feature. It is a validated co-measurement that grades steatosis from S0 (no meaningful fat) through S3 (severe steatosis, ≥67% hepatocytes involved). In MASLD staging, the combination of elevated CAP with rising LSM carries worse cardiovascular and hepatic outcomes than either marker alone [4].

Standard Diagnostic Cutoffs Versus Longevity Targets

Diagnostic cutoffs and longevity targets are not the same number. Diagnostic cutoffs flag existing disease. Longevity targets define the physiologic range associated with the lowest all-cause and liver-specific mortality.

Diagnostic Cutoffs by Fibrosis Stage

The EASL 2021 position paper and subsequent 2023 CPG define the following M-probe (standard adult) cutoffs after at least 2 hours of fasting [3]:

| Fibrosis Stage | Histological Definition | LSM Cutoff (kPa) | |---|---|---| | F0 | No fibrosis | <5.0 | | F1 | Portal fibrosis, no septa | 5.0 to 7.9 | | F2 | Portal fibrosis with few septa | ≥8.0 to 9.6 | | F3 | Numerous septa, no cirrhosis | ≥9.7 to 13.5 | | F4 | Cirrhosis | ≥13.6 |

These cutoffs carry an AUROC of 0.84 for F2+ and 0.92 for cirrhosis in MASLD populations when using the M-probe after a 2-hour fast [3].

The Longevity Target: Below 7.0 kPa

A population-level cohort of 11,576 participants in the Rotterdam Study found that every 1-kPa increase in LSM above 7.0 kPa was associated with a 7% increase in all-cause mortality after adjustment for age, sex, BMI, and metabolic comorbidities [5]. The 7.0 kPa threshold represents the upper boundary of F0, F1, where fibrosis is absent or only periportal without bridging. Longevity-medicine practice therefore targets LSM strictly below 7.0 kPa, tighter than the diagnostic cutoff for significant fibrosis.

The Caution Zone: 7.0 to 9.6 kPa

LSM in the 7.0 to 9.6 kPa range does not yet meet the diagnostic threshold for significant fibrosis (F2+), but it is not benign. The LITMUS consortium (N=3,012, 14 European centers) showed that subjects in this intermediate zone had a 3.1-fold higher rate of liver-related events over 5 years compared with subjects below 7.0 kPa [6]. This zone triggers intensified metabolic intervention in longevity practice, including GLP-1 receptor agonist initiation, dietary carbohydrate restriction, and serial monitoring every 6 to 12 months rather than every 2 to 3 years.

MASLD Staging and Clinical Decision Points

F0, F1 (<8.0 kPa): Lifestyle and Surveillance

Patients in this range have no or minimal fibrosis. The primary interventions are lifestyle: 7 to 10% body-weight loss, Mediterranean dietary pattern, and aerobic exercise at 150 minutes per week of moderate intensity [7]. The 2023 American Association for the Study of Liver Diseases (AASLD) Practice Guidance on MASLD states, "Weight loss of at least 5% improves hepatic steatosis; loss of 7 to 10% improves histologic features of MASH including fibrosis" [7]. Surveillance FibroScan every 2 to 3 years is adequate when metabolic risk factors are controlled.

F2 (8.0 to 9.6 kPa): Resmetirom Eligibility Begins

F2 fibrosis is the entry criterion for resmetirom (Rezdiffra, Madrigal Pharmaceuticals), the first FDA-approved pharmacotherapy for MASH with fibrosis. The FDA approved resmetirom in March 2024 on the basis of the MAESTRO-NASH trial (N=966), where resmetirom 80 mg or 100 mg daily for 52 weeks achieved MASH resolution without worsening fibrosis in 25.9% (80 mg) and 29.9% (100 mg) of patients versus 9.7% for placebo (P<0.001), and fibrosis improvement of at least one stage without MASH worsening in 24.2% and 25.9% respectively versus 14.2% placebo (P<0.001) [8]. Patients enrolled had F2 or F3 fibrosis confirmed by biopsy.

In clinical practice, when biopsy is not available, VCTE ≥8.2 kPa combined with a FIB-4 score above 1.3 provides an acceptable non-invasive surrogate for F2+ disease per the AASLD 2023 guidance [7].

F3 (9.7 to 13.5 kPa): High-Priority Intervention

F3 fibrosis carries a hepatocellular carcinoma (HCC) incidence rate of approximately 0.5 to 2.3% per year even without cirrhosis [9]. At this stage, resmetirom at 100 mg daily is the preferred dose per the prescribing information [8]. Semi-annual ultrasound surveillance for HCC is appropriate. Referral to hepatology is standard. The MAESTRO-NASH OUTCOMES trial is ongoing and will report cardiovascular and liver-event outcomes at 54 months; interim data at 24 months showed LSM reduction of 1.4 kPa in the resmetirom 100 mg arm (P<0.001 vs. Placebo) [8].

F4 (≥13.6 kPa): Cirrhosis Management

Cirrhosis confirmation requires integration of LSM with clinical, laboratory, and imaging data. VCTE alone misclassifies up to 15% of F3 patients as F4 in the presence of acute hepatic inflammation, congestive heart failure, or extrahepatic cholestasis [3]. When LSM exceeds 20 kPa, the positive predictive value for cirrhosis exceeds 90% without liver biopsy [3]. Management shifts to varices screening, HCC surveillance every 6 months, and assessment for liver transplantation listing.

Controlled Attenuation Parameter (CAP) Targets

Steatosis Grades and CAP Cutoffs

The CAP score grades steatosis using the following validated thresholds for the M-probe [1]:

| Steatosis Grade | Hepatocyte Involvement | CAP Cutoff (dB/m) | |---|---|---| | S0 | <5% | <238 | | S1 | 5 to 33% | 238 to 259 | | S2 | 34 to 66% | 260 to 280 | | S3 | ≥67% | >280 |

Longevity Target for CAP

The longevity-medicine target is S0, meaning CAP below 238 dB/m, corresponding to less than 5% hepatocyte fat content. A meta-analysis of 17 prospective cohorts (total N=22,827) published in the Journal of Hepatology found that S2, S3 steatosis at baseline was associated with a hazard ratio of 1.45 for major adverse cardiovascular events (MACE) over a mean 7.2-year follow-up, independent of BMI and lipid panel [4]. This cardiovascular signal makes CAP a longevity biomarker, not merely a liver biomarker.

CAP and GLP-1 Receptor Agonist Response

Semaglutide 2.4 mg weekly (Wegovy) reduced hepatic steatosis by one CAP grade in 62% of patients with MASH and BMI above 27 kg/m2 in a 72-week single-arm substudy of the STEP program [10]. The ESSENCE trial (NCT04822181), a dedicated Phase 3 MASH study of semaglutide 2.4 mg, completed enrollment in 2024 and is expected to report primary fibrosis endpoints in 2025. Patients with CAP ≥260 dB/m and LSM ≥8.2 kPa represent the highest-priority GLP-1 candidate group in current longevity practice.

Measurement Conditions That Affect Accuracy

A single number from a FibroScan machine is only as reliable as the acquisition conditions. The following variables directly inflate LSM and generate false-positive fibrosis staging.

Fasting State

Postprandial hepatic blood flow increases liver stiffness by 1.5 to 2.0 kPa in non-cirrhotic subjects [3]. All measurements should occur after a minimum 2-hour fast. A 4-hour fast is preferred for patients with diabetes or known gastroparesis, where gastric emptying is delayed.

IQR/Median Ratio

The interquartile range to median ratio (IQR/M) must be below 30% for a reliable result. An IQR/M of 30% or above reduces AUROC for F3+ fibrosis from 0.92 to 0.74 in MASLD cohorts [1]. Reports without IQR/M disclosed should be treated as preliminary.

Probe Selection

The M-probe applies to the majority of adults. The XL probe is required when skin-to-liver capsule distance exceeds 25 mm (estimated by BMI above 30 kg/m2 or subcutaneous fat depth on ultrasound). XL-probe cutoffs for F2+ shift upward by approximately 1.5 kPa relative to M-probe cutoffs [3]. Comparing M-probe and XL-probe results across serial studies in the same patient introduces systematic error.

Hepatic Inflammation

Active hepatitis (ALT above 5 times the upper limit of normal), congestive hepatomegaly, and biliary obstruction each increase LSM independent of fibrosis stage. In these conditions, VCTE should be repeated after treatment of the acute process [3].

Serial Monitoring Intervals in Longevity Practice

How often a patient repeats FibroScan depends on baseline LSM, trajectory of metabolic markers, and whether pharmacotherapy has been initiated. The following intervals reflect current AASLD and EASL guidance adapted for longevity-medicine surveillance [3][7]:

| Baseline LSM | Metabolic Risk | Recommended Interval | |---|---|---| | <5.0 kPa, CAP <238 | Low (no MASLD criteria) | Every 3 to 5 years | | 5.0 to 6.9 kPa, CAP <260 | Moderate (1 to 2 metabolic risk factors) | Every 2 years | | 7.0 to 8.1 kPa, CAP ≥260 | Moderate-High (active intervention) | Every 12 months | | 8.2 to 9.6 kPa (F2) | High (pharmacotherapy initiated) | Every 6 to 12 months | | ≥9.7 kPa (F3+) | Very High | Every 6 months + hepatology |

A decrease of 1.5 kPa or more from baseline, sustained over two consecutive measurements, is considered a clinically meaningful response in published trials evaluating pharmacological and lifestyle interventions for MASH [8][6].

FibroScan in the Context of a Longevity Panel

FibroScan does not operate in isolation. It is most informative when paired with the following co-tests:

FIB-4 Index

FIB-4 (age × AST / [platelet count × √ALT]) below 1.3 has a negative predictive value of 90% for F3+ fibrosis, allowing VCTE to be triaged rather than performed universally [7]. FIB-4 above 2.67 has a positive predictive value of 80% for F3+ and should prompt VCTE regardless of symptoms [7].

Enhanced Liver Fibrosis (ELF) Score

The ELF score (hyaluronic acid, PIIINP, TIMP-1) adds serum-based fibrosis information that complements VCTE when LSM falls in the 7.0 to 9.6 kPa grey zone. ELF above 9.8 reclassifies borderline-LSM patients into higher fibrosis probability categories with 83% concordance with biopsy in the LITMUS validation set [6].

Liver Enzymes and Metabolic Markers

ALT, AST, GGT, insulin resistance (HOMA-IR), and uric acid provide the metabolic context that explains why LSM is elevated. An LSM of 8.5 kPa with normal ALT and BMI below 25 should raise clinical suspicion for a non-MASLD etiology (alcohol, hereditary hemochromatosis, alpha-1 antitrypsin deficiency) before MASLD is assumed.

Resmetirom Prescribing: VCTE as Gatekeeper

The FDA label for resmetirom (Rezdiffra) specifies F2 or F3 MASH confirmed by either liver biopsy or non-invasive testing meeting predefined thresholds [8]. In centers without ready biopsy access, VCTE ≥8.2 kPa combined with at least one of the following serves as the standard non-invasive confirmation package per the AASLD 2023 guidance [7]:

• FIB-4 above 1.3
• ELF score above 9.8
• MRI-PDFF (proton density fat fraction) above 5%

Resmetirom is a liver-directed thyroid hormone receptor beta (THR-β) agonist dosed at 80 mg or 100 mg daily based on body weight (80 mg for <100 kg, 100 mg for ≥100 kg) [8]. The MAESTRO-NASH trial primary endpoints (MASH resolution and fibrosis improvement) both reached statistical significance. The drug is not currently indicated for F0, F1 disease, and off-label use at those stages has no controlled trial support.

What a Longevity Clinician Communicates to the Patient

Translating kPa numbers into actionable patient language requires consistency. The following framing reflects best practices from the AASLD Communication Guidance and is used by the HealthRX clinical team:

"A score below 7 means your liver shows no signs of scarring right now. A score between 7 and 9.5 means early changes that respond well to diet, exercise, and sometimes medication. A score above 9.5 means we need to act more aggressively and involve a liver specialist."

Numbers between 5 and 7 should not be presented as "normal" to longevity-medicine patients. They represent F0, F1, which is structurally benign but signals early metabolic liver burden that responds to intervention before fibrosis progresses.